Nuclear receptor CAR-mediated liver cancer and its species differences

References

• Barrett JC. Mechanisms of multistep carcinogenesis and carcinogen risk assessment. Environ Health Perspect. 1993;100:9–20.
   Google Scholar
• Cohen SM, Arnold LL. Chemical carcinogenesis. Toxicol Sci. 2011;120(Suppl 1):S76–92.
   Google Scholar
• Columbano A, Ledda-Columbano GM. Mitogenesis by ligands of nuclear receptors: an attractive model for the study of the molecular mechanisms implicated in liver growth. Cell Death Differ. 2003;10(Suppl 1):S19–21.
   Google Scholar
• Vacca M, Degirolamo C, Massafra V, et al. Nuclear receptors in regenerating liver and hepatocellular carcinoma. Mol Cell Endocrinol. 2013;368:108–119.
   Google Scholar
• Handschin C, Meyer UA. Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev. 2003;55:649–673.
   Google Scholar
• Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002;1:259–266.
   Google Scholar
• Yamamoto Y, Moore R, Goldsworthy TL, et al. The orphan nuclear receptor constitutive active/androstane receptor is essential for liver tumor promotion by phenobarbital in mice. Cancer Res. 2004;64:7197–7200.
   Google Scholar
• IARC. Phenobarbital and its sodium salt in “IARC Monographs on the evaluation of carcinogencic riskst humans”. Vol. 79, Some thyreotropic agents. Lyon (France): IARC; 2001. p. 161–288.
   Google Scholar
• Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol. 2009;90:367–386.
   Google Scholar
• Huang W, Zhang J, Washington M, et al. Xenobiotic stress induces hepatomegaly and liver tumors via the nuclear receptor constitutive androstane receptor. Mol Endocrinol. 2005;19:1646–1653.
   Google Scholar
• Tamura K, Inoue K, Takahashi M, et al. A crucial role of constitutive androstane receptor (CAR) in liver tumor development by imazalil in mice. J Toxicol Sci. 2016;41:801–811.
   Google Scholar
• Wang Z, Li X, Wu Q, et al. Toxaphene-induced mouse liver tumorigenesis is mediated by the constitutive androstane receptor. J Appl Toxicol. 2017;37:967–975.
   Google Scholar
• Kettner NM, Voicu H, Finegold MJ, et al. Circadian homeostasis of liver metabolism suppresses hepatocarcinogenesis. Cancer Cell. 2016;30:909–924.
   Google Scholar
• Blanco-Bose WE, Murphy MJ, Ehninger A, et al. C-Myc and its target FoxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology. 2008;48:1302–1311.
   Google Scholar
• Ledda-Columbano GM, Pibiri M, Loi R, et al. Early increase in cyclin-D1 expression and accelerated entry of mouse hepatocytes into S phase after administration of the mitogen 1, 4-Bis[2-(3,5-Dichloropyridyloxy)] benzene [Research Support, Non-U.S. Gov’t]. Am J Pathol. 2000;156:91–97.
   Google Scholar
• Ledda-Columbano GM, Pibiri M, Concas D, et al. Sex difference in the proliferative response of mouse hepatocytes to treatment with the CAR ligand, TCPOBOP. Carcinogenesis. 2003;24:1059–1065.
   Google Scholar
• Costa RH, Kalinichenko VV, Tan Y, et al. The CAR nuclear receptor and hepatocyte proliferation. Hepatology. 2005;42:1004–1008.
   Google Scholar
• Moore JT, Moore LB, Maglich JM, et al. Functional and structural comparison of PXR and CAR. Biochim Biophys Acta. 2003;1619:235–238.
   Google Scholar
• Shizu R, Benoki S, Numakura Y, et al. Xenobiotic-induced hepatocyte proliferation associated with constitutive active/androstane receptor (CAR) or peroxisome proliferator-activated receptor alpha (PPARalpha) is enhanced by pregnane X receptor (PXR) activation in mice. PLoS One. 2013;8:e61802.
   Google Scholar
• Staudinger J, Liu Y, Madan A, et al. Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos. 2001;29:1467–1472.
   Google Scholar
• Pondugula SR, Pavek P, Mani S. Pregnane X receptor and cancer: context-specificity is key. Nucl Receptor Res. 2016;3:101198.
   Google Scholar
• Aydinlik H, Nguyen TD, Moennikes O, et al. Selective pressure during tumor promotion by phenobarbital leads to clonal outgrowth of β-catenin-mutated mouse liver tumors. Oncogene. 2001;20:7812–7816.
   Google Scholar
• Rignall B, Braeuning A, Buchmann A, et al. Tumor formation in liver of conditional beta-catenin-deficient mice exposed to a diethylnitrosamine/phenobarbital tumor promotion regimen. Carcinogenesis. 2011;32:52–57.
   Google Scholar
• Mattu S, Saliba C, Sulas P, et al. High frequency of beta-catenin mutations in mouse hepatocellular carcinomas induced by a non-genotoxic constitutive androstane receptor agonist. Am J Pathol. 2018;188:2497–2507.
   Google Scholar
• Braeuning A, Heubach Y, Knorpp T, et al. Gender-specific interplay of signaling through beta-catenin and CAR in the regulation of xenobiotic-induced hepatocyte proliferation. Toxicol Sci. 2011;123:113–122.
   Google Scholar
• Ganzenberg K, Singh Y, Braeuning A. The time point of beta-catenin knockout in hepatocytes determines their response to xenobiotic activation of the constitutive androstane receptor. Toxicology. 2013;308:113–121.
   Google Scholar
• Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
   Google Scholar
• Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4:a008052.
   Google Scholar
• Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A. 1999;96:5522–5527.
   Google Scholar
• Zhang S, Li Y, Wu Y, et al. Wnt/beta-catenin signaling pathway upregulates c-Myc expression to promote cell proliferation of P19 teratocarcinoma cells. Anat Rec (Hoboken). 2012;295:2104–2113.
   Google Scholar
• de La Coste A, Romagnolo B, Billuart P, et al. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci U S A. 1998;95:8847–8851.
   Google Scholar
• Strathmann J, Schwarz M, Tharappel JC, et al. PCB 153, a non-dioxin-like tumor promoter, selects for beta-catenin (Catnb)-mutated mouse liver tumors. Toxicol Sci. 2006;93:34–40.
   Google Scholar
• Kondo Y, Kanai Y, Sakamoto M, et al. Beta-catenin accumulation and mutation of exon 3 of the beta-catenin gene in hepatocellular carcinoma. Jpn J Cancer Res. 1999;90:1301–1309.
   Google Scholar
• Wong CM, Fan ST, Ng IO. beta-Catenin mutation and overexpression in hepatocellular carcinoma: clinicopathologic and prognostic significance. Cancer. 2001;92:136–145.
   Google Scholar
• Huang H, Fujii H, Sankila A, et al. Beta-catenin mutations are frequent in human hepatocellular carcinomas associated with hepatitis C virus infection. Am J Pathol. 1999;155:1795–1801.
   Google Scholar
• Zeng G, Apte U, Cieply B, et al. siRNA-mediated beta-catenin knockdown in human hepatoma cells results in decreased growth and survival. Neoplasia. 2007;9:951–959.
   Google Scholar
• Schreiber S, Rignall B, Braeuning A, et al. Phenotype of single hepatocytes expressing an activated version of beta-catenin in liver of transgenic mice. J Mol Histol. 2011;42:393–400.
   Google Scholar
• Harada N, Miyoshi H, Murai N, et al. Lack of tumorigenesis in the mouse liver after adenovirus-mediated expression of a dominant stable mutant of beta-catenin. Cancer Res. 2002;62:1971–1977.
   Google Scholar
• Harada N, Tamai Y, Ishikawa T, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. Embo J. 1999;18:5931–5942.
   Google Scholar
• Dong B, Lee JS, Park YY, et al. Activating CAR and beta-catenin induces uncontrolled liver growth and tumorigenesis. Nat Commun. 2015;6:5944.
   Google Scholar
• Harada N, Oshima H, Katoh M, et al. Hepatocarcinogenesis in mice with beta-catenin and Ha-ras gene mutations. Cancer Res. 2004;64:48–54.
   Google Scholar
• Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A. 2004;101:17216–17221.
   Google Scholar
• Braeuning A, Gavrilov A, Geissler M, et al. Tumor promotion and inhibition by phenobarbital in livers of conditional Apc-deficient mice. Arch Toxicol. 2016;90:1481–1494.
   Google Scholar
• Awuah PK, Rhieu BH, Singh S, et al. beta-Catenin loss in hepatocytes promotes hepatocellular cancer after diethylnitrosamine and phenobarbital administration to mice. PLoS One. 2012;7:e39771.
   Google Scholar
• Johnson R, Halder G. The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment. Nat Rev Drug Discov. 2014;13:63–79.
   Google Scholar
• Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: hippo signaling and beyond. Physiol Rev. 2014;94:1287–1312.
   Google Scholar
• Zheng T, Wang J, Jiang H, et al. Hippo signaling in oval cells and hepatocarcinogenesis. Cancer Lett. 2011;302:91–99.
   Google Scholar
• Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120–1133.
   Google Scholar
• Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747–2761.
   Google Scholar
• Xu MZ, Yao T-J, Lee NPY, et al. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 2009;115:4576–4585.
   Google Scholar
• Kowalik MA, Saliba C, Pibiri M, et al. Yes-associated protein regulation of adaptive liver enlargement and hepatocellular carcinoma development in mice. Hepatology. 2011;53:2086–2096.
   Google Scholar
• Donthamsetty S, Bhave VS, Kliment CS, et al. Excessive hepatomegaly of mice with hepatocyte-targeted elimination of integrin linked kinase following treatment with 1,4-bis [2-(3,5-dichaloropyridyloxy)] benzene. Hepatology. 2011;53:587–595.
   Google Scholar
• Perra A, Kowalik MA, Ghiso E, et al. YAP activation is an early event and a potential therapeutic target in liver cancer development. J Hepatol. 2014;61:1088–1096.
   Google Scholar
• Bhushan B, Stoops JW, Mars WM, et al. TCPOBOP-induced hepatomegaly and hepatocyte proliferation are attenuated by combined disruption of MET and EGFR signaling. Hepatology. 2019;69:1702–1718.
   Google Scholar
• Abe T, Amaike Y, Shizu R, et al. Role of YAP activation in nuclear receptor CAR-mediated proliferation of mouse hepatocytes. Toxicol Sci. 2018;165:408–419.
   Google Scholar
• Maglich JM, Parks DJ, Moore LB, et al. Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. J Biol Chem. 2003;278:17277–17283.
   Google Scholar
• Moore LB, Parks DJ, Jones SA, et al. Orphan nuclear receptors constitutive androstane receptor and pregnane X receptor share xenobiotic and steroid ligands. J Biol Chem. 2000;275:15122–15127.
   Google Scholar
• Mutoh S, Sobhany M, Moore R, et al. Phenobarbital indirectly activates the constitutive active androstane receptor (CAR) by inhibition of epidermal growth factor receptor signaling. Sci Signal. 2013;6:ra31.
   Google Scholar
• Shizu R, Osabe M, Perera L, et al. Phosphorylated nuclear receptor CAR forms a homodimer to repress its constitutive activity for ligand activation. Mol Cell Biol. 2017;37:e00649–16.
   Google Scholar
• Blattler SM, Rencurel F, Kaufmann MR, et al. In the regulation of cytochrome P450 genes, phenobarbital targets LKB1 for necessary activation of AMP-activated protein kinase. Proc Natl Acad Sci U S A. 2007;104:1045–1050.
   Google Scholar
• Whysner J, Ross PM, Williams GM. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol Ther. 1996;71:153–191.
   Google Scholar
• Parzefall W, Erber E, Sedivy R, et al. Testing for induction of DNA synthesis in human hepatocyte primary cultures by rat liver tumor promoters [Research Support, Non-U.S. Gov’t]. Cancer Res. 1991;51:1143–1147.
   Google Scholar
• Okuda Y, Kushida M, Kikumoto H, et al. Evaluation of the human relevance of the constitutive androstane receptor-mediated mode of action for rat hepatocellular tumor formation by the synthetic pyrethroid momfluorothrin. J Toxicol Sci. 2017;42:773–788.
   Google Scholar
• Soldatow V, Peffer RC, Trask OJ, et al. Development of an in vitro high content imaging assay for quantitative assessment of CAR-dependent mouse, rat, and human primary hepatocyte proliferation. Toxicol In Vitro. 2016;36:224–237.
   Google Scholar
• Hirose Y, Nagahori H, Yamada T, et al. Comparison of the effects of the synthetic pyrethroid Metofluthrin and phenobarbital on CYP2B form induction and replicative DNA synthesis in cultured rat and human hepatocytes. Toxicology. 2009;258:64–69.
   Google Scholar
• Tateno C, Miya F, Wake K, et al. Morphological and microarray analyses of human hepatocytes from xenogeneic host livers. Lab Invest. 2013;93:54–71.
   Google Scholar
• Yamada T, Okuda Y, Kushida M, et al. Human hepatocytes support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogen sodium phenobarbital in an in vivo study using a chimeric mouse with humanized liver. Toxicol Sci. 2014;142:137–157.
   Google Scholar
• Scheer N, Ross J, Rode A, et al. A novel panel of mouse models to evaluate the role of human pregnane X receptor and constitutive androstane receptor in drug response. J Clin Invest. 2008;118:3228–3239.
   Google Scholar
• Ross J, Plummer SM, Rode A, et al. Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol Sci. 2010;116:452–466.
   Google Scholar
• Braeuning A, Gavrilov A, Brown S, et al. Phenobarbital-mediated tumor promotion in transgenic mice with humanized CAR and PXR. Toxicol Sci. 2014;140(2):259–270.
   Google Scholar
• Luisier R, Lempiainen H, Scherbichler N, et al. Phenobarbital induces cell cycle transcriptional responses in mouse liver humanized for constitutive androstane and pregnane X receptors. Toxicol Sci. 2014;139:501–511.
   Google Scholar
• Braeuning A, Schwarz M. Is the question of phenobarbital as potential liver cancer risk factor for humans really resolved? Arch Toxicol. 2016;90:1525–1526.
   Google Scholar
• Moya IM, Castaldo SA, Van den Mooter L, et al. Peritumoral activation of the Hippo pathway effectors YAP and TAZ suppresses liver cancer in mice. Science. 2019;366:1029–1034.
   Google Scholar
• Shizu R, Abe T, Benoki S, et al. PXR stimulates growth factor-mediated hepatocyte proliferation by cross-talk with the FOXO transcription factor. Biochem J. 2016;473:257–266.
   Google Scholar
• Jiang Y, Feng D, Ma X, et al. Pregnane X receptor regulates liver size and liver cell fate via yes-associated protein activation. Hepatology. 2019;69:343–358.
   Google Scholar
• Dai G, He L, Bu P, et al. Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology. 2008;47:1277–1287.
   Google Scholar
• Abe T, Shizu R, Sasaki T, et al. Functional interaction between pregnane X receptor and yes-associated protein in xenobiotic-dependent liver hypertrophy and drug metabolism. J Pharmacol Exp Ther. 2019;371:590–601.
   Google Scholar
• Burger PC, Herdson PB. Phenobarbital-induced fine structural changes in rat liver. Am J Pathol. 1966;48:793–809.
   Google Scholar
• Japundzic M, Knezevic B, Djordjevic-Camba V, et al. The influence of phenobarbital-NA on the mitotic activity of parenchymal liver cells during rat liver regeneration. Exp Cell Res. 1967;48:163–167.
   Google Scholar
• Peraino C, Fry RJ, Staffeldt E. Reduction and enhancement by phenobarbital of hepatocarcinogenesis induced in the rat by 2-acetylaminofluorene. Cancer Res. 1971;31:1506–1512.
   Google Scholar
• Peraino C, Fry RJ, Staffeldt E. Brief communication: enhancement of spontaneous hepatic tumorigenesis in C3H mice by dietary phenobarbital. J Natl Cancer Inst. 1973;51:1349–1350.
   Google Scholar
• Wei P, Zhang J, Egan-Hafley M, et al. The nuclear receptor CAR mediates specific xenobiotic induction of drug metabolism. Nature. 2000;407:920–923.
   Google Scholar
• Honkakoski P, Zelko I, Sueyoshi T, et al. The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol. 1998;18:5652–5658.
   Google Scholar
• Plummer S, Beaumont B, Wallace S, et al. Cross-species comparison of CAR-mediated procarcinogenic key events in a 3D liver microtissue model. Toxicol Rep. 2019;6:998–1005.
   Google Scholar
• Tao J, Calvisi DF, Ranganathan S, et al. Activation of beta-catenin and Yap1 in human hepatoblastoma and induction of hepatocarcinogenesis in mice. Gastroenterology. 2014;147:690–701.
   Google Scholar
• Rosenbluh J, Nijhawan D, Cox AG, et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell. 2012;151:1457–1473.
   Google Scholar
• Deng F, Peng L, Li Z, et al. YAP triggers the Wnt/β-catenin signalling pathway and promotes enterocyte self-renewal, regeneration and tumorigenesis after DSS-induced injury. Cell Death Dis. 2018;9:153.
   Google Scholar
• Mendoza-Reinoso V, Beverdam A. Epidermal YAP activity drives canonical WNT16/beta-catenin signaling to promote keratinocyte proliferation in vitro and in the murine skin. Stem Cell Res. 2018;29:15–23.
   Google Scholar
• Park HW, Kim YC, Yu B, et al. Alternative Wnt signaling activates YAP/TAZ. Cell. 2015;162:780–794.
   Google Scholar
• Azzolin L, Zanconato F, Bresolin S, et al. Role of TAZ as mediator of Wnt signaling. Cell. 2012;151:1443–1456.
   Google Scholar
• Azzolin L, Panciera T, Soligo S, et al. YAP/TAZ incorporation in the beta-catenin destruction complex orchestrates the Wnt response. Cell. 2014;158:157–170.
   Google Scholar
• Kormish JD, Sinner D, Zorn AM. Interactions between SOX factors and Wnt/beta-catenin signaling in development and disease. Dev Dyn. 2010;239:56–68.
   Google Scholar
• Yi C, Shen Z, Stemmer-Rachamimov A, et al. The p130 isoform of angiomotin is required for Yap-mediated hepatic epithelial cell proliferation and tumorigenesis. Sci Signal. 2013;6:ra77.
   Google Scholar
• Kolluri A, Ho M. The Role of glypican-3 in regulating Wnt, YAP, and hedgehog in liver cancer. Front Oncol. 2019;9:708.
   Google Scholar
• Feng M, Gao W, Wang R, et al. Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Natl Acad Sci U S A. 2013;110:E1083–91.
   Google Scholar
• Lin CW, Mars WM, Paranjpe S, et al. Hepatocyte proliferation and hepatomegaly induced by phenobarbital and 1,4-bis [2-(3,5-dichloropyridyloxy)] benzene is suppressed in hepatocyte-targeted glypican 3 transgenic mice. Hepatology. 2011;54:620–630.
   Google Scholar
• Stine ZE, Walton ZE, Altman BJ, et al. MYC, metabolism, and cancer. Cancer Discov. 2015;5:1024–1039.
   Google Scholar
• Lin C-P, Liu C-R, Lee C-N, et al. Targeting c-Myc as a novel approach for hepatocellular carcinoma. World J Hepatol. 2010;2:16–20.
   Google Scholar
• Katoh M, Igarashi M, Fukuda H, et al. Cancer genetics and genomics of human FOX family genes. Cancer Lett. 2013;328:198–206.
   Google Scholar
• Osabe M, Sugatani J, Takemura A, et al. Expression of CAR in SW480 and HepG2 cells during G1 is associated with cell proliferation. Biochem Biophys Res Commun. 2008;369:1027–1033.
   Google Scholar
• Raj N, Bam R. Reciprocal crosstalk between YAP1/Hippo pathway and the p53 family proteins: mechanisms and outcomes in cancer. Front Cell Dev Biol. 2019;7:159.
   Google Scholar
• Damalas A, Ben-Ze’ev A, Simcha I, et al. Excess beta-catenin promotes accumulation of transcriptionally active p53. Embo J. 1999;18:3054–3063.
   Google Scholar
• Schulte-Hermann R, Bursch W, Grasl-Kraupp B, et al. Apoptosis and multistage carcinogenesis in rat liver. Mutat Res. 1995;333:81–87.
   Google Scholar
• Negishi M. Phenobarbital meets phosphorylation of nuclear receptors. Drug Metab Dispos. 2017;45:532–539.
   Google Scholar
• Shan L, Vincent J, Brunzelle JS, et al. Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism. Mol Cell. 2004 Dec;22(16):907–917.
   Google Scholar
• Shizu R, Min J, Sobhany M, et al. Interaction of the phosphorylated DNA-binding domain in nuclear receptor CAR with its ligand-binding domain regulates CAR activation. J Biol Chem. 2018;293:333–344.
   Google Scholar